RUNX1 and Miyoshi myopathy: Initially, germline RUNX1 variants were classified as pathogenic if associated with FPD‐MM phenotype, but the discovery of new variants in cancer patients with no history of thrombocytopenia or familial haematological diseases is questioning this assertion.